Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.47 USD | +3.16% | +5.00% | -34.08% |
Business Summary
Number of employees: 36
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Innovative Medicines
100.0
%
| 13 | 100.0 % | 5 | 100.0 % | -61.32% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 13 | 100.0 % | 5 | 100.0 % | -61.32% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 59 | 15-05-31 | |
Ivor MacLeod
DFI | Director of Finance/CFO | 63 | 22-10-23 |
Daniella Gigante
CTO | Chief Tech/Sci/R&D Officer | - | 20-09-30 |
Nkechi Azie
CTO | Chief Tech/Sci/R&D Officer | - | 19-06-09 |
Debbie Etchison
IRC | Investor Relations Contact | - | 21-07-31 |
Glen D. Park
LAW | General Counsel | - | 16-12-31 |
Scott Sukenick
LAW | General Counsel | 46 | 17-11-14 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Armando Anido
BRD | Director/Board Member | 66 | 19-01-20 |
David Hastings
BRD | Director/Board Member | 62 | 15-09-23 |
Ann Hanham
BRD | Director/Board Member | 71 | 08-11-30 |
Guy MacDonald
CHM | Chairman | 65 | 14-11-26 |
Steven Gilman
BRD | Director/Board Member | 71 | 15-02-24 |
Chief Executive Officer | 59 | 15-05-31 | |
Brian Tinmouth
BRD | Director/Board Member | 60 | 19-12-12 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 37,207,799 | 36,135,699 ( 97.12 %) | 0 | 97.12 % |
Company contact information
SCYNEXIS, Inc.
1 Evertrust Plaza 13th floor
07302-6548, Jersey City
+201 884 5485
http://www.scynexis.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.08% | 54.7M | |
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+0.74% | 209B | |
+2.95% | 212B | |
-6.05% | 205B | |
-3.61% | 157B |
- Stock
- Equities
- Stock SCYNEXIS, Inc. - Nasdaq
- Company SCYNEXIS, Inc.